Abstract:
The present invention provides the amino acid and nucleotide sequence of a protein that binds to beta 3 integrins, alpha IIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling.
Abstract:
Novel purinergic receptors are provided, having research, diagnostic and therapeutic applications. Also provided are nucleic acids encoding these receptors, as well as expression systems for their production.
Abstract:
Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
Abstract:
A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a compound of formula (I), wherein: R1 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, polyaromatic, polyaromatic carbonyl, polyheteroaromatic or polyheteroaromatic carbonyl; R2 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, lower hydrocarboyl, 5- or 6-membered heterocyclic aromatic carbonyl, polyaromatic or polyheteroaromatic; R3 is H or lower alkyl; R5 is H, lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, halogen, or cyano; and R6 is H or lower hydrocarboyl. 00000
Abstract translation:公开了选择性抑制激酶的方法,其包括将含有激酶的组合物与式(I)化合物接触,其中:R 1是低级烷基,低级烃基,芳基低级烷基,杂芳基低级烷基,5-或6- 多芳基,多芳基羰基,多杂芳基或多杂芳基羰基; R 2是低级烷基,低级烃基,芳基低级烷基,杂芳基低级烷基,5-或6-元杂环芳族,低级烃基,5-或6-元杂环芳族羰基,多芳族或多杂芳族; R3是H或低级烷基; R5是H,低级烷基,低级烃基,芳基低级烷基,杂芳基低级烷基,5-或6-元杂环芳族,卤素或氰基; R6为H或低级烃基。 00000
Abstract:
A (injectable biologically active) polypeptide is stabilized by dissolving said polypeptide forming a liquid solution in citrate buffer of about pH 5.0-5.5.
Abstract:
Cell lines and methods for high efficiency production of soluble peptides having platelet-derived growth factor (PDGF) ligand binding activity. Cell lines are provided which secrete soluble fragments from extracellular regions of PDGF receptor (PDGF-R) polypeptides. Methods using these cell lines for production of the fragments are also provided.
Abstract:
Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
Abstract:
Disclosed are polypeptides and nucleic acids encoding same. Also disclodes are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.
Abstract:
Disclosed are polypeptides and nucleic acids encoding same. Also disclodes are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.
Abstract:
The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.